• Publications
  • Influence
Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
Background:Trastuzumab has recently shown efficacy in the treatment of HER2-positive advanced gastric adenocarcinoma. Although antibody-based therapies target the metastatic disease, HER2 status isExpand
  • 127
  • 5
  • PDF
EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.
The fusion gene EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) was recently identified as a novel genetic alteration in non-small cell lungExpand
  • 111
  • 4
PTEN status in advanced colorectal cancer treated with cetuximab
Background:Loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN) function in advanced colorectal cancer (CRC) may represent one of the resistance mechanisms to cetuximab byExpand
  • 76
  • 4
  • PDF
Bcl‐2 expression on fine‐needle aspirates from primary breast carcinoma
The bcl‐2 gene encodes for a protein that is involved in cell death regulation. It frequently is expressed in breast tumors, in which it is associated with favorable prognostic factors. It has beenExpand
  • 19
  • 4
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
A number of different clinical characteristics and molecular markers related to epidermal growth factor receptor (EGFR) activation have been reported to singly correlate with therapeutic activity ofExpand
  • 67
  • 3
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.
Abstract With the advent of third-generation epidermal growth-factor receptor (EGFR) tyrosine kinase inhibitors, such as AZD9291 and CO-1686, new mechanisms of drug resistance are emerging, likeExpand
  • 73
  • 3
FGFR as potential target in the treatment of squamous non small cell lung cancer.
To date therapeutic options for squamous cell lung cancer patients remain scarce because no druggable targets have been identified so far. Aberrant signaling by FGFs (fibroblast growth factors) andExpand
  • 41
  • 3
Multifactorial central nervous system recurrence susceptibility in patients with HER2‐positive breast cancer
A series of retrospective studies have reported that patients with human epidermal growth factor receptor 2(HER2)‐positive breast cancer are at a greater risk of central nervous system (CNS)Expand
  • 104
  • 2
HER‐2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma
Amplification of the HER‐2/neu oncogene has been proposed as a target for antibody‐based therapies and as a predictor of chemoresponsiveness in advanced breast carcinoma. Few studies haveExpand
  • 43
  • 2
  • PDF
Fine-needle aspiration technique for the concurrent immunocytochemical evaluation of multiple biologic parameters in primary breast carcinoma
SummaryFine-needle aspiration cytology has been already established as a reliable method for the diagnosis of breast cancer. Its application has been recently extended to immunocytochemical analysisExpand
  • 29
  • 2